Heartflow AI Software Shows Major Impact on Cardiac Care Decisions

Heartflow's AI Plaque Analysis software leads to significant improvements in cholesterol management and cardiac risk reduction in coronary artery disease patients.

Key Details

• DECIDE Registry, the largest prospective study of its kind, enrolled ~20,000 CAD patients at 30+ US clinical sites.
• Heartflow AI Plaque Analysis prompted treatment changes in over 50% of patients versus CCTA alone.
• Patients managed using the software saw mean LDL cholesterol reductions of 18.7 mg/dL.
• A 15% estimated reduction in cardiac event risk was observed for these patients.
• Significant management changes occurred even in patients with no calcified plaque.
• The AI provides individualized risk insights by quantifying and characterizing all plaque types, including non-calcified, soft plaques.

Why It Matters

This large-scale prospective evidence demonstrates that adding AI-based plaque quantification to CCTA can materially change patient management, with potential to reduce adverse cardiac events. These results highlight the growing role of imaging AI in personalizing cardiovascular care.

Read more